[ad_1]
From “this is the most promising vaccine so far” by Ursula von der Leyen, president of the European Commission, until “November 9, 2020 will be remembered as a symbolic date in the war against Covid-19” by virologist Guido Silvestri, a professor at Emory University in Atlanta. It is difficult to follow the comments that around the world draw the scene around Pfizer’s anti-Covid vaccine. The hopes of the whole world turn their gaze to the American company that, together with the German BioNTech, announced yesterday the effectiveness of 90% of the vaccine that should defeat the Coronavirus.
Coronavirus, double record in Abruzzo: 746 cases of almost 5,000 swabs. Asl L’Aquila communicates 21 dead
Speaking of Ursula von der Leyen, here is the announcement that starts the European planning: “Tomorrow we authorize a contract for a maximum of 300 million doses of the vaccine developed by the German company BioNTech and Pfizer.” Once the vaccine is available, he added “our plan is to distribute it quickly, anywhere in Europe.” A common vision to make the immediate future strategy even stronger: “This is the most promising vaccine so far. And it is the fourth contract with a pharmaceutical company for the purchase of vaccines – von Der Leyen recalled – and others will arrive. Because we need a large portfolio of vaccines based on different technologies. We have already started working with the Member States to prepare national vaccination campaigns. We are almost there – he concluded – in the meantime, we must be cautious and be safe ».
The agreement of the EU Commission with Pfizer-Biontech for the purchase of 300 million doses of the vaccine for Covid-19 will be on the agenda of the college of commissioners tomorrow. Community Executive Spokesperson Eric Mamer announced. Tomorrow’s decision is crucial, the Member States will then decide under what conditions to participate.
Covid, Brazil suspends Sinovac vaccine test: “Serious accident”
From the point of view of scientists, as mentioned, November 9 is a historic date: “This is a decisive phase of the final battle,” Guido Silvestri underlined on Facebook. “As we know from studies and other data that are being published, LY-CoV555 (this is the name of the vaccine) significantly reduces (72-90%) the risk of hospitalization if administered at the onset of the first symptoms, with similar efficacy in at-risk subjects (over 65 years and BMI over 35). A result that, if confirmed, would be very important to relieve hospital pressure. At this point, at least in the United States, the way is open, from from the institutional and regulatory point of view, for the use of this drug in patients in the initial phase of Covid-19, and we hope to be able to solve the obvious logistical problems (distribution, storage, contracting, etc.) soon and start using carpets. “
Last updated: 17:09
© REPRODUCTION RESERVED
[ad_2]
